Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant MMP9 (Andecaliximab Biosimilar) antibody

The Human Monoclonal anti-MMP9 (Andecaliximab Biosimilar) antibody (ABIN7675795) specifically detects MMP9 (Andecaliximab Biosimilar) in ELISA, BLI, FACS, Func and SPR. The antibody is reactive with Human samples.
Catalog No. ABIN7675795
$346.15
Plus shipping costs $50.00
Shipping to: United States
Delivery in 10 to 12 Business Days

Quick Overview for Recombinant MMP9 (Andecaliximab Biosimilar) antibody (ABIN7675795)

Target

MMP9 (Andecaliximab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
  • 1
  • 1
Human

Clonality

  • 2
Monoclonal

Conjugate

  • 2
This MMP9 (Andecaliximab Biosimilar) antibody is un-conjugated

Application

ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
  • Expression System

    CHO Cells

    Purpose

    Anti-MMP9 Reference Antibody (andecaliximab)

    Sequence

    QVQLQESGPG LVKPSETLSL TCTVSGFSLL SYGVHWVRQP PGKGLEWLGV IWTGGTTNYN SALMSRFTIS KDDSKNTVYL KMNSLKTEDT AIYYCARYYY GMDYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK,DIQMTQSPSS LSASVGDRVT ITCKASQDVR NTVAWYQQKP GKAPKLLIYS SSYRNTGVPD RFSGSGSGTD FTLTISSLQA EDVAVYYCQQ HYITPYTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC

    Characteristics

    Anti-MMP9 Reference Antibody (andecaliximab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

    Purity

    >95 %

    Isotype

    IgG4 S228P
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Comment

    Therapeutic Agents by Target and Mechanism: MMP9 inhibitors

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Concentration

    1 mg/mL

    Buffer

    25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

    Storage

    4 °C,-80 °C

    Storage Comment

    +4°C,-80°C
  • Target

    MMP9 (Andecaliximab Biosimilar)

    Target Type

    Biosimilar

    Molecular Weight

    145.5 kDa

    UniProt

    P14780
You are here:
Chat with us!